Skip to main content

Meprobamate Pregnancy and Breastfeeding Warnings

Brand names: Equanil, MB-TAB, Miltown

Medically reviewed by Drugs.com. Last updated on Jun 12, 2024.

Meprobamate Pregnancy Warnings

Use should be avoided especially during the first trimester

Risk Summary: An increased risk of congenital malformations has been associated with minor tranquilizers including this drug.

Comments: Women of childbearing potential should be advised of risks.

An increased risk of congenital malformations during the first trimester of pregnancy has been suggested. This drug passes the placental barrier and is present in the umbilical cord blood at or near maternal plasma levels.

See references

Meprobamate Breastfeeding Warnings

Use is not recommended

Excreted into human milk: Yes

Comment: Monitor infant for sedation, especially if mother is concurrently taking other drugs that may cause sedation.

Breast milk concentrations of this drug have been found to be up to 4 times those in maternal plasma. While it may not be a reason to discontinue breastfeeding, other agents may be preferred due to limited information available with this drug.

See references

See also

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2016) "Product Information. Meprobamate (meprobamate)." Alembic Pharmaceuticals

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
  3. (2016) "Product Information. Meprobamate (meprobamate)." Alembic Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer